Allergy Therapeutics plc
AGY.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.11 | -0.15 | 0.01 |
| FCF Yield | -6.02% | -2.95% | -13.24% | -18.73% |
| EV / EBITDA | -18.56 | -51.69 | -9.25 | -6.58 |
| Quality | ||||
| ROIC | -53.42% | -13.32% | -50.91% | -27.38% |
| Gross Margin | 20.31% | 61.30% | 42.62% | 61.12% |
| Cash Conversion Ratio | 0.73 | 0.69 | 0.89 | 1.38 |
| Growth | ||||
| Revenue 3-Year CAGR | -12.14% | -11.89% | -8.92% | -7.95% |
| Free Cash Flow Growth | -149.40% | 60.87% | -85.06% | 49.71% |
| Safety | ||||
| Net Debt / EBITDA | -2.06 | -3.76 | -0.86 | 0.38 |
| Interest Coverage | -5.82 | -2.30 | -23.20 | -3.73 |
| Efficiency | ||||
| Inventory Turnover | 1.20 | 1.11 | 0.97 | 1.10 |
| Cash Conversion Cycle | 84.79 | 6.66 | 95.86 | -29.88 |